FDA Cherry-Picking Record In Sensipar Case, Amgen Says
Amgen Inc. accused the U.S. Food and Drug Administration Wednesday of limiting evidence in the company's exclusivity bid for blockbuster calcium-control drug Sensipar, prompting a D.C. federal judge to ask that...To view the full article, register now.
Already a subscriber? Click here to view full article